Assistant professor of Pediatrics, University of Pennsylvania School of Medicine
AddressThe Children's Hospital of Philadelphia Colket Translational Research Building, Room 3008 3501 Civic Center Boulevard
My clinical interests include pediatric leukemia and autoimmune disease with emphasis on acute lymphoblastic leukemia, lymphoproliferative disorders, and hematopoietic stem cell transplant.
My basic science research focuses on two areas. My first area of interest centers on signal transduction pathways and inhibitors of those pathways in acute lymphoblastic leukemia (ALL). My lab targets a number of signaling pathways with novel therapeutics and uses xenograft models to study the efficacy of agents and mechanism of action of those agents directly on leukemia cells obtained from children. This work has led to a number of nationwide Children's Oncology Group-initiated clinical trials testing novel agents in patients with ALL. Recently, I have started to focus on investigating novel agents in very high risk subsets of ALL, including T-ALL.
The other major area of basic research in my lab centers on investigating novel therapeutics and signaling pathways in autoimmune diseases. I focus on a rare pediatric disorder called autoimmune lymphoproliferative syndrome (ALPS). Using preclinical models, I am targeting both mTOR and Notch signaling as treatment approaches for patients with ALPS and other autoimmune diseases. I am also interested in understanding lymphocyte biology in ALPS and other autoimmune diseases.
My clinical research is focused on investigating novel therapies for children with ALL and ALPS. I am on the study committee for a number of national childhood ALL trials, performing correlative biology for many of these studies. I am also the principal investigator for a local (CHOP) clinical trial that is using the mTOR inhibitor rapamycin in children with multiple medical conditions, including ALPS, chronic ITP, and lupus.
- Assistant Professor of Pediatrics at the Children's Hospital of Philadelphia (2013– present)
- Assistant Professor of Pediatrics at University of Pennsylvania School of Medicine (2007 – 2013)
- MD, Medicine, Eastern Virginia Medical School (1999)
- BS, Magna cum laude with Honors in Biology, Virginia Commonwealth University (1993)
My expertise is in both oncology and hematology. Although the majority of my time is spent in the laboratory, I enjoy taking care of patients at Children's Hospital. My research has given me a broad clinical approach that helps me diagnose and treat the rare child who is "off the grid," particularly when there is an oncology/hematology problem that has gone unsolved. I also specialize in hematopoietic stem cell transplant (bone marrow transplant) and use my expertise in transplant to help treat patients with leukemia and autoimmune diseases.
My clinical research is focused on better understanding diseases of white blood cells in children, in particular acute lymphoblastic leukemia (ALL) and a rare disorder called autoimmune lymphoproliferative syndrome (ALPS). I focus on creating novel therapeutics for leukemia and ALPS, and have been successful in bringing drugs from the bench to the bedside to treat children with these conditions.
I am involved in the Children's Oncology Group, developing clinical trials for patients ALL. Recently, I have focused on moving new agents into clinical trials for patients with T cell ALL. I am involved with leukemia trials, using agents that target a number of key pathways, including aurora kinase, mTOR, and Notch. I am on the study committee for a number of these trials and am currently Vice Chair for three early phase trials.
I am also the principal investigator for a clinical trial that is using the mTOR inhibitor rapamycin (sirolimus) in children with multiple medical conditions. mTOR is a key protein in a pathway that regulates cell activities including growth and survival. The autoimmune conditions we are looking at in this trial include ALPS, chronic Immune Thrombocytopenic Purpura (ITP, a blood disorder that involves the immune and blood clotting systems) and lupus (a chronic, inflammatory autoimmune disorder.) I also run an ongoing multi-institutional trial to diagnose and better characterize children with ALPS.
My basic science research focuses on the same two areas: acute lymphoblastic leukemia and autoimmune diseases. My first area of interest is the signal transduction pathways and inhibitors of those pathways in acute lymphoblastic leukemia (ALL). My lab targets the a number of signaling pathway, including PI3K/Akt/mTOR and Notch with novel therapeutics. We use xenograft (tissue grafts from one species to another) models to study the efficacy and action of those therapeutic agents directly on leukemia cells removed from children. Currently, we are focusing studying new therapies for a number of high risk ALL subsets.
The other major area of basic research in my lab centers on investigating novel therapeutics and signaling pathways in autoimmune diseases, particularly ALPS. Using preclinical models, I am targeting PI3K/Akt/mTOR and Notch cell signaling as treatment approaches for patients with ALPS and other autoimmune diseases. I am also interested in understanding lymphocyte biology in ALPS and other autoimmune diseases. At Children's Hospital, we are somewhat unique in that we value and excel at both patient care and basic science and clinical science. We are able to put our full weight on all the pathways to help children with cancer and blood disorders.
- Teachey DT, Manno CS, Axsom KM, Andrews T, Choi JK, Greenbaum BH, McMann JM, Sullivan KE, Travis SF, Grupp SA. Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). Blood. Vol 105(6) . 2005 March:2443-8.
- Teachey DT, Obzut DA, Axsom K, Choi JK, Goldsmith KC, Hall J, Hulitt J, Manno CS, Maris JM, Rhodin N, Sullivan KE, Brown VI, Grupp SA. Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS). Blood. Vol 108(6) . 2006 September:1965-71.
- Teachey DT, Greiner R, Seif A, Attiyeh E, Bleesing J, Choi J, Manno C, Rappaport E, Schwabe D, Sheen C, Sullivan KE, Zhuang H, Wechsler DS, Grupp SA. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br J Haematol. Vol 145(1) . 2009 April:101-6.
- Teachey DT, Seif AE, Brown VI, Bruno M, Bunte RM, Chang Y, Choi JK, Fish JD, Hall J, Reid GS, Ryan T, Sheen C, Zweidler-McKay P, Grupp SA.. Targeting notch signaling in autoimmune and lymphoproliferative disease.. Blood. Vol 111(2) . 2008 January:705-14.
- Teachey DT, Obzut DA, Cooperman J, Fang J, Carroll M, Choi JK, Houghton PJ, Brown VI, Grupp SA. The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood. Vol 107(3) . 2006 February:1149-55.
- Teachey DT, Sheen C, Hall J, Ryan T, Brown VI, Fish J, Reid GS, Seif AE, Norris R, Chang YJ, Carroll M, Grupp SA. mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Blood. Vol 112(5) . 2008 September:2020-3.
- Teachey DT. Neonatal MRI and neurodevelopmental outcomes.. N Engl J Med. Vol 355(22) . 2006 November:2374.
- Teachey DT, Grupp SA, and Brown VI. Mammalian target of rapamycin inhibitors and their potential role for therapy in leukemia and other haematologic malignancies. Br J Haematol. Vol 145(5) . 2009 June:569-80.
- Seif AE, Manno CS, Sheen C, Grupp SA, and Teachey DT. Identifying autoimmune lymphoproliferative syndrome (ALPS) in children with Evans syndrome: a multi-institutional study. Blood. Vol 115(11) . 2010 March:2142-5.
- Teachey DT, Seif AE, Grupp SA. Advances in the managment and understanding of autoimmune lymphoproliferative syndrome (ALPS). Br J Haematol. Vol 148(2) . 2010 January:205-16.